Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 8/20 | 0.90 |
| ▸ | DRD3 | P35462 | 7/20 | 0.90 |
| ▸ | HTR1D | P28221 | 2/20 | 0.67 |
| ▸ | HTR1B | P28222 | 1/20 | 0.67 |
| ▸ | DRD4 | P21917 | 3/20 | 0.59 |
| ▸ | CA1 | P00915 | 4/20 | 0.57 |
| ▸ | CA2 | P00918 | 4/20 | 0.57 |
| ▸ | ACHE | P22303 | 4/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.57 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.57 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.53 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11488842 | 0.99 | DRD2 (0.87) | DRD2DRD3HTR1DHTR1BDRD4 | |
| SCHEMBL8394614 | 0.94 | DRD2 (1.00) | DRD2DRD3HTR1DHTR1BDRD4 | |
| SCHEMBL2702018 | 0.94 | DRD2 (1.00) | DRD2DRD3HTR1DHTR1BDRD4 | |
| SCHEMBL2701521 | 0.94 | DRD2 (1.00) | DRD2DRD3HTR1DHTR1BDRD4 | |
| Hydrochloric Acid SCHEMBL6339640 | 0.93 | DRD2 (0.97) | DRD2DRD3HTR1DHTR1BDRD4 | |
| SCHEMBL11493562 | 0.89 | DRD2 (0.71) | DRD2DRD3HTR1DHTR1BDRD4 | |
| SCHEMBL8689197 | 0.88 | DRD2 (0.79) | DRD2DRD3HTR1DHTR1BDRD4 | |
| SCHEMBL9757841 | 0.87 | DRD2 (0.86) | DRD2DRD3HTR1DHTR1BDRD4 | |
| Hydrochloric Acid SCHEMBL11443133 | 0.87 | DRD2 (0.69) | DRD2DRD3HTR1DHTR1BDRD4 | |
| SCHEMBL6334450 | 0.82 | DRD2 (0.78) | DRD2DRD3HTR1DHTR1BDRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120041225-A1 | KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF | VAIDYA NITEEN A (US) | 2012-02-16 | — | — | US | claimed |
| US-20070185346-A1 | Kit for automated resolving agent selection and method thereof | VAIDYA NITEEN A | 2007-08-09 | — | — | US | claimed |
| US-20120041225-A1 | KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF | VAIDYA NITEEN A (US) | 2012-02-16 | — | — | US | disclosed |
| EP-1981831-A2 | KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF | Vaidya, Niteen A. (US) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007092264-A2 | KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF | VAIDYA NITEEN A (US) | 2007-08-16 | — | — | WO | disclosed |
| US-20070185346-A1 | Kit for automated resolving agent selection and method thereof | VAIDYA NITEEN A | 2007-08-09 | — | — | US | disclosed |
| EP-0055043-B1 | 6,7,8,9-TETRAHYDRO-3H-BENZ(E)INDOLAMINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND INTERMEDIATES USED THEREIN, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE INDOLAMINE DERIVATIVES | AYERST, MCKENNA AND HARRISON INC. (CA) | 1985-01-23 | — | — | EP | disclosed |
| US-4454150-A | 6,7,8,9-Tetrahydro-3H-benz(e)indol-7-amines and a method of dopamine receptor stimulation therewith | AYERST, MCKENNA & HARRISON INC. (US) | 1984-06-12 | — | — | US | disclosed |
| EP-0055043-A2 | 6,7,8,9-Tetrahydro-3H-benz(e)indolamine derivatives, processes for their preparation and intermediates used therein, and pharmaceutical compositions containing the indolamine derivatives | AYERST, MCKENNA AND HARRISON INC. (CA) | 1982-06-30 | — | — | EP | disclosed |
| EP-0041488-A1 | Therapeutically useful tetralin derivatives | Arvidsson, Folke Lars-Erik (SE) | 1981-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041225-A1 | KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF | ACKR3, KIT, C3AR1 | DRD2 1686/4885DRD3 1126/4885HTR1D 1634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.